Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biovail affirms CNS focus in $100mm Prestwick takeover

Executive Summary

Biovail has acquired privately held Prestwick Pharmaceuticals (neurology) for $100mm. The deal was structured in part around the out-licensing of Prestwick's first FDA-approved drug for Huntington's disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech
    • Intra-Biotech Deal
    • Full Acquisition

Related Companies

UsernamePublicRestriction

Register